Localizing Pathologic Response After Neoadjuvant Immunotherapy for Stage III Melanoma
Tyeese L. Gaines DO interviews Alexander CJ van Akkooi MD, PhD on Localizing Pathologic Response After Neoadjuvant Immunotherapy for Stage III Melanoma
Video originally published on PracticeUpdate.com on 10/22/2018 -- https://www.practiceupdate.com/content/esmo-2018-localizing-pathologic-response-after-neoadjuvant-immunotherapy-for-stage-iii-melanoma/75120/45/1/3
--
Follow PracticeUpdate:
Twitter: https://twitter.com/practiceupdate
Facebook: https://www.facebook.com/practiceupdate
Instagram: https://www.instagram.com/practiceupdate_elsevier
LinkedIn: https://www.linkedin.com/showcase/practiceupdate
Register for PracticeUpdate for free at https://www.practiceupdate.com/welcome
Видео Localizing Pathologic Response After Neoadjuvant Immunotherapy for Stage III Melanoma канала PracticeUpdate
Video originally published on PracticeUpdate.com on 10/22/2018 -- https://www.practiceupdate.com/content/esmo-2018-localizing-pathologic-response-after-neoadjuvant-immunotherapy-for-stage-iii-melanoma/75120/45/1/3
--
Follow PracticeUpdate:
Twitter: https://twitter.com/practiceupdate
Facebook: https://www.facebook.com/practiceupdate
Instagram: https://www.instagram.com/practiceupdate_elsevier
LinkedIn: https://www.linkedin.com/showcase/practiceupdate
Register for PracticeUpdate for free at https://www.practiceupdate.com/welcome
Видео Localizing Pathologic Response After Neoadjuvant Immunotherapy for Stage III Melanoma канала PracticeUpdate
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
Efficacy of T-VEC in Early Metastatic Melanoma
ASCO 2017: Clinical Relevance BRAF Mutations in Thyroid Cancer
The Immune Landscape of Residual TNBC After Neoadjuvant Chemotherapy
Heroin/Opioid Addiction Among Cancer Patients – Recommendations for Patients
A Review of Immunotherapy and Targeted Therapy in Glioblastoma
New Concepts in Metastatic Prostate Cancer
Salvage vs Adjuvant Therapy in High-Risk Prostate Cancer
Erlotinib Plus Ramucirumab for EGFR Mutant Lung Cancer
Redefining Cisplatin-Eligibility for Muscle-Invasive Bladder Cancer
Expression Score (Escore) for Predicting Recurrence of DCIS
Practice Implications of Real World Data on First-Line Pazopanib in mRCC
Current Concepts in Initial and Adjuvant RCC Treatment
Metastatic Breast Cancer: Triple Negative
PCI versus medical therapy for patients with symptomatic coronary artery disease?
Gene Therapy for Advanced Parkinson’s Disease
Lenvatinib and Everolimus for the Treatment of RCC
New Data on Pancreatic Cancer from ASCO GI
Schizophrenia: Acute vs Chronic Management
Adjuvant T-DM1 for Stage I HER2+ Breast Cancer
Depression Management: First-Line Treatments
Adding Immunotherapy to First-Line Chemotherapy for Gastric Cancer: Data From ATTRACTION-4